Compare FIP & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIP | ENTA |
|---|---|---|
| Founded | 2021 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 567.5M | 486.3M |
| IPO Year | N/A | 2013 |
| Metric | FIP | ENTA |
|---|---|---|
| Price | $5.38 | $13.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $11.00 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 905.9K | 371.2K |
| Earning Date | 02-26-2026 | 02-09-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $439,767,000.00 | $65,324,000.00 |
| Revenue This Year | $60.92 | $0.99 |
| Revenue Next Year | $57.57 | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.39 | N/A |
| 52 Week Low | $3.10 | $4.09 |
| 52 Week High | $8.28 | $17.15 |
| Indicator | FIP | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 65.89 | 46.90 |
| Support Level | $4.85 | $14.07 |
| Resistance Level | $5.21 | $13.98 |
| Average True Range (ATR) | 0.24 | 0.80 |
| MACD | 0.07 | -0.25 |
| Stochastic Oscillator | 97.86 | 27.27 |
FTAI Infrastructure Inc is engaged in five segments; Railroad segment includes five freight railroads and one switching company that provide rail service to certain manufacturing and production facilities, the Jefferson Terminal segment consists of a multi-modal crude oil and refined products terminal and other related assets. Repauno segment consists of a 1,630-acre deep-water port located along the Delaware River with an underground storage cavern, a new multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities. Power and Gas segment is comprised of an equity method investment in Long Ridge, and Sustainability and Energy Transition segment is comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.